Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

Aaron Waxman discusses research into patients with pulmonary hypertension due to interstitial lung disease and the effects of inhaled treprostinil.  Aaron B. Waxman is the director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital (BWH). He is also an associate professor of medicine at Harvard Medical School.

Image courtesy of Aaron Waxman

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Article

Tipping Point for Online Learning?

Next Article

Assessing the Assessment

×
As a guest, you have insight(s) remaining for this month. Create a free account to view 300 more.
Related Posts
error: Faculti Content is protected. Please check our Privacy Policy and Terms and Conditions.

Add the Faculti Web App to your Mobile or Desktop homescreen

Install
×